Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Shimizu, Hiroaki  [Clear All Filters]
2024
Kurihara K, Sadato D, Najima Y, Hirama C, Haraguchi K, Kato K, Kondo K, Sadaga Y, Kato C, Sakai S, et al. [FLT3-ITD mutation-positive acute myeloid leukemia undergoing clonal transition with PTPN11 mutation at relapse]. Rinsho Ketsueki. 2024;65(2):63-68.
Nishijima A, Shingai N, Ohta A, Suda K, Omoto K, Ishida S, Yoshioka K, Kurosawa S, Hino Y, Senoo Y, et al. [Kidney transplantation for end-stage renal disease after third allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia]. Rinsho Ketsueki. 2024;65(1):7-12.
Kambara Y, Sadato D, Toya T, Honda A, Kato S, Hirama C, Haraguchi K, Shimizu H, Najima Y, Kobayashi T, et al. Recurrent DDX41 mutation in very late relapse after allogeneic stem cell transplantation. Leukemia. 2024.
Koi S, Shimizu H, Sadaga Y, Kondo K, Kato C, Sakai S, Kambara Y, Konuma R, Atsuta Y, Shimabukuro M, et al. [Ruptured mycotic cerebral aneurysm in an adult T-cell leukemia/lymphoma patient undergoing allogeneic stem cell transplantation]. Rinsho Ketsueki. 2024;65(2):84-89.
2023
Shingai N, Ota A, Kato K, Kondo K, Sadaga Y, Kato C, Sakai S, Kambara Y, Nabe Y, Asano K, et al. Elevation of urinary liver-type fatty acid-binding protein is a harbinger of poor patient prognosis after allogeneic stem cell transplantation. Transplant Cell Ther. 2023.
Morita Y, Yagi Y, Kanemasa Y, Sasaki Y, Ishimine K, Hayashi Y, Mino M, Ohigashi A, Tamura T, Nakamura S, et al. [Polatuzumab vedotin, bendamustine, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, including the outcome as a bridging treatment to CAR-T cell therapy or allogeneic hematopoietic stem cell transplant]. Rinsho Ketsueki. 2023;64(7):586-595.
Harada K, Onizuka M, Mori T, Shimizu H, Seo S, Aotsuka N, Takeda Y, Sekiya N, Kusuda M, Fujihara S, et al. Prognostic factors for the development of lower respiratory tract infection after influenza virus infection in allogeneic hematopoietic stem cell transplantation recipients: A KSGCT Multicenter Analysis. Int J Infect Dis. 2023.
2022
Shirane S, Najima Y, Fukushima K, Sekiya N, Funata N, Kishida Y, Nagata A, Yamada Y, Konishi T, Kaito S, et al. Central nervous system mucormycosis in a patient with hematological malignancy: A case report and review of the literature. J Infect Chemother. 2022.
2021
Yagi Y, Kanemasa Y, Ohigashi A, Morita Y, Tamura T, Nakamura S, Otsuka Y, Kishida Y, Kageyama A, Shimizuguchi T, et al. Chimeric antigen receptor T-cell therapy following autologous transplantation for secondary central nervous system lymphoma: A case report. Medicine (Baltimore). 2021;100(44):e27733.
Yasuda S, Najima Y, Konishi T, Yamada Y, Nagata A, Takezaki T, Kaito S, Kurosawa S, Sakaguchi M, Harada K, et al. Outcome of allogeneic hematopoietic stem cell transplantation for T-cell lymphoblastic leukemia/lymphoma: A single-center study. Leuk Res. 2021;108:106627.
2020
Akahoshi Y, Kimura S-I, Inamoto Y, Seo S, Muranushi H, Shimizu H, Ozawa Y, Tanaka M, Uchida N, Kanda Y, et al. Effect of cytomegalovirus reactivation with or without acute graft-versus-host disease on the risk of nonrelapse mortality. Clin Infect Dis. 2020.
Kikuchi T, Mori T, Ohwada C, Onoda M, Shimizu H, Yokoyama H, Onizuka M, Koda Y, Kato J, Takeda Y, et al. Pharmacokinetics of intravenous busulfan as condition for hematopoietic stem cell transplantation: comparison between combinations with cyclophosphamide and fludarabine. Int J Hematol. 2020.
2019
Kako S, Kanda Y, Onizuka M, Aotsuka N, Usuki K, Tachibana T, Kobayashi T, Kato J, Yano S, Shimizu H, et al. Allogeneic hematopoietic stem cell transplantation for aplastic anemia with pre-transplant conditioning using fludarabine, reduced-dose cyclophosphamide, and low-dose thymoglobulin: a KSGCT prospective study. Am J Hematol. 2019.
Ohwada C, Sakaida E, Igarashi A, Kobayashi T, Doki N, Mori T, Kato J, Koda Y, Kanamori H, Tanaka M, et al. A Prospective, Longitudinal Observation of the Incidence, Treatment, and Survival of Late Acute and Chronic Graft-versus-host disease by National Institutes of Health Criteria in a Japanese cohort. Biol Blood Marrow Transplant. 2019.
2018
Akahoshi Y, Mizuta S, Shimizu H, Uchida N, Fukuda T, Kanamori H, Onizuka M, Ozawa Y, Ohashi K, Ohta S, et al. Additional cytogenetic abnormalities with Philadelphia chromosome-positive acute lymphoblastic leukemia on allogeneic stem cell transplantation in the tyrosine kinase inhibitor era. Biol Blood Marrow Transplant. 2018.